By Mary Ellen McIntire; Morning Consult ~ Mar 06, 2017
Drugmakers have pointed to pharmacy benefit managers as a force behind rising drug prices in the U.S., but Americans don’t appear to have a gloomier view of one industry group over the other, according to Morning Consult Brands Intelligence data.
U.S. adults don’t have significantly higher favorability rates for certain pharmaceutical and biotechnology companies as opposed to pharmacies, suppliers and pharmacy benefit managers, according to surveys of more than 22,000 American adults from October to March.